SCHEMBL24089977

SCHEMBL24089977

O=c1c2cc(Cl)ccc2nc(Nc2ccc(CN3CCOCC3)cc2)n1-c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.47
MAPT P10636 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
LMNA P02545 2/20 0.47
MEN1 O00255 2/20 0.47
MAPK1 P28482 1/20 0.47
IDO1 P14902 1/20 0.45
TDO2 P48775 1/20 0.45
IDO2 Q6ZQW0 1/20 0.45
P2RX3 P56373 1/20 0.45
ACP1 P24666 2/20 0.45
JAK2 O60674 1/20 0.44
SYK P43405 1/20 0.44
MAT2A P31153 1/20 0.43
ALDH1A1 P00352 4/20 0.43
TSHR P16473 2/20 0.43
RAB9A P51151 3/20 0.42
NPC1 O15118 2/20 0.42
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29623222 1.00 KMT2A (0.47) KMT2AMAPTSMN1; SMN2LMNAMEN1
SCHEMBL23065073 0.91 ACP1 (0.48) SMN1; SMN2IDO1TDO2IDO2ACP1
SCHEMBL29623202 0.90 ACP1 (0.52) KMT2AMEN1MAPK1ACP1ALDH1A1
SCHEMBL23065072 0.90 ACP1 (0.52) KMT2AMEN1MAPK1ACP1ALDH1A1
SCHEMBL23065082 0.90 IDO1 (0.55) KMT2ASMN1; SMN2MEN1IDO1TDO2
SCHEMBL29623297 0.90 IDO1 (0.55) KMT2ASMN1; SMN2MEN1IDO1TDO2
SCHEMBL29623149 0.86 ACP1 (0.39) KMT2ASMN1; SMN2MEN1ACP1JAK2
SCHEMBL24090108 0.86 ACP1 (0.39) KMT2ASMN1; SMN2MEN1ACP1JAK2
SCHEMBL23064459 0.85 LMNA (0.39) MAPTSMN1; SMN2LMNAACP1RAB9A
SCHEMBL24089897 0.85 ACP1 (0.40) MAPTSMN1; SMN2LMNAACP1MAT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352366-B2 2-aminoquinazolinone derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-06-07 US disclosed
US-20220143020-A1 2-AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-05-12 US disclosed
US-20210380598-A1 2-AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2021-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220143020-A1 2-AMINOQUINAZOLINONE DERIVATIVE CNKSR1, HAX1, CRKL KMT2A 1257/4885MAPT 4827/4885SMN1; SMN2 2556/4885
US-20210380598-A1 2-AMINOQUINAZOLINONE DERIVATIVE CNKSR1, HAX1, SLC26A3 KMT2A 967/4885MAPT 4783/4885SMN1; SMN2 2469/4885
US-11352366-B2 2-aminoquinazolinone derivative CNKSR1, HAX1, SLC26A3 KMT2A 967/4885MAPT 4783/4885SMN1; SMN2 2469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.